Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997610 | 0.86 | CHRM3 (0.35) | CHRNA7KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL2390266 | 0.79 | TDP1 (0.31) | — | |
| SCHEMBL21057055 | 0.72 | ADORA3 (0.44) | CHRNA7KCNH2 | |
| SCHEMBL31053525 | 0.70 | TDP1 (0.34) | CHRNA7CHRM2CHRM4CHRM5 | |
| SCHEMBL6859733 | 0.70 | TDP1 (0.39) | — | |
| SCHEMBL19381894 | 0.69 | CHRNA7 (0.58) | CHRNA7KCNH2 | |
| SCHEMBL26235665 | 0.69 | CHRNA7 (0.58) | CHRNA7KCNH2 | |
| SCHEMBL26554807 | 0.69 | CHRNA7 (0.33) | CHRNA7KCNH2HSD11B1 | |
| SCHEMBL18513255 | 0.67 | — | — | |
| SCHEMBL10206098 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | CHRNA7 4854/4885KCNH2 4857/4885CHRM2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.